SNY

Sanofi

$ 49.13

 Earnings are forecast to grow

 Trading below its fair value

SNY Risk Level

SNY Analysts Opinion

SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

SNY Performance Sentiment

Sanofi (SNY) Q1 Earnings In Line Sales Miss Estimates Stock Up. Sanofi SNY reported first-quarter 2024 adjusted earnings of 96 cents per American depositary share in line with the Zacks Consensus Estimate. Earnings of &euro.1.78 per share declined 17.6% on a reported basis and 7.4% on a constant c

Thu Apr 25, 2024

Sanofi Reports Strong Earnings Joins Kirby Sonic Automotive Union Pacific And Other Big Stocks Moving Higher On Thursday. United States stocks were lower with the Dow Jones falling over 600 points on Thursday.Shares of ) rose sharply during Thursday'.s session following better-than-expected first-quarter earnings.Sanofi reported first-quarter operating income of 2.8 billion euros down 14.7% Y/Y and 4.2% on constant currency. The French drugmaker reported adjusted EPS of 97 cents (1.78 euros)

Thu Apr 25, 2024

Press Release: Sanofi Q1: robust 7% sales growth driven by launches underpins full-year guidance. Sanofi Q1: robust 7% sales growth driven by launches underpins full-year guidance(1) of €1.78 down 17.6% reported and 7.4% at CER(1) to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit(2) at CER including the higher expected tax rate barring unforeseen major adverse events. Applying average April 2024 exchange rates the curren

Thu Apr 25, 2024

Sanofi Sales Profit Beat Forecasts. Sanofi backed its full-year earnings guidance after it reported first-quarter profit ahead of consensus with sales growth driven by continued strength in anti-inflammatory drug Dupixent and its new drug launches.

Thu Apr 25, 2024

Sanofi Q1 Profit Drops Sales Rise. Confirms FY24 Outlook . (RTTNews) - French drug major Sanofi (SNYNF SNY) reported Thursday that its first-quarter net income attributable to equity holders on IFRS basis was 1.13 billion euros down 43.2 percent from last years 2 billion euros.

Thu Apr 25, 2024

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study. Sanofi SNY announced positive data from the phase III LUNA 3 study which evaluated its covalent BTK inhibitor rilzabrutinib for treating patients with immune thrombocytopenia (ITP) an autoimmune blood disorder.

Tue Apr 23, 2024

Understanding Merck &. Cos Position In Pharmaceuticals Industry Compared To Competitors. In today'.s rapidly evolving and fiercely competitive business landscape it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article we will undertake an in-depth industry comparison assessing Merck &. Co (NYSE:) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining crucial financial indicators market positio

Tue Apr 23, 2024

Sanofi succeeds in late-stage trial for blood disorder candidate.

Tue Apr 23, 2024

Sanofi: Rilzabrutinib LUNA 3 Phase 3 Study Meets Primary Endpoint In Immune Thrombocytopenia . (RTTNews) - Sanofi - Aventis Groupe said results from the LUNA 3 phase 3 study showed that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia. The safety profile w

Tue Apr 23, 2024

Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals. Amidst today'.s fast-paced and highly competitive business environment it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article we will delve into an extensive industry comparison evaluating Eli Lilly and Co (NYSE:) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing critical financial metrics market positio

Fri Apr 19, 2024

Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry. In today'.s rapidly changing and highly competitive business world it is vital for investors and industry enthusiasts to carefully assess companies. In this article we will perform a comprehensive industry comparison evaluating Regeneron Pharmaceuticals (NASDAQ:) against its key competitors in the Biotechnology industry. By analyzing important financial metrics market position and growth prospects we aim to

Thu Apr 18, 2024

Why IGM Biosciences Is Rising In Pre-market? . (RTTNews) - IGM Biosciences Inc. (IGMS) said the companys collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets. IGM will retain global rights to its technology related to the oncology targ

Wed Apr 17, 2024

Sanofis Multiple Sclerosis Antibody Shows Reduction Of Disease Activity. )  Wednesday new data from a Phase 2 study in relapsing multiple sclerosis.These 48-week data showed that treatment with frexalimab resulted in further decreases in the number of lesions and a sustained reduction in disease activity. The preliminary clinical results are promising with a very low annual relapse rate said Patrick Vermersch.Also Read: In Heart Burn Drug Zantac’.s Litigation Saga Sanofi ...

Wed Apr 17, 2024

IGM Biosciences announces refocusing of Sanofi collaboration.

Wed Apr 17, 2024

Nurix gains after extending Sanofi research pact.

Tue Apr 9, 2024

BlackBerry Nurix Therapeutics Tesla And Other Big Stocks Moving Higher On Tuesday. United States stocks were lower with the Dow Jones index falling over 200 points on Tuesday.Shares of ) rose .The company announced a collaboration with ) designed to revolutionize next-generation robotic systems by enabling new levels of low latency and jitter as well as repeatable determinism.BlackBerry shares jumped 9% to $3.1340 on Tuesday.Here are some other big stocks recording losses in today&rsquo.s sessio

Tue Apr 9, 2024

Assessing Johnson &. Johnsons Performance Against Competitors In Pharmaceuticals Industry. Amidst today'.s fast-paced and highly competitive business environment it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article we will delve into an extensive industry comparison evaluating Johnson &. Johnson (NYSE:) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing critical financial metrics market

Tue Apr 9, 2024

Sanofi Announces Launch of Verorab ® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups.

Fri Apr 5, 2024